{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67","upperLimit":"96","value":"81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Duration of response is measure as time between hematologic response and hematologic progression.\n\nHematologic progression is defined as 50% increase from nadir.\n\nWhile duration of response was assessed up to 4 years, 4 year estimates were not reached. We are reporting the 24 month estimate (how many participants achieved 24 month duration of response)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Isatuximab"}],"paramType":"NUMBER","populationDescription":"27 participants with response to study treatment","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Duration of Response (24 Month Estimate)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}